NCT01999777View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Epilepsy

Interventions

DRUG

USL261

DRUG

Placebo

Trial Locations (51)

Unknown

Phoenix

Tucson

La Jolla

Orange

San Francisco

Denver

Englewood

New Haven

Tampa

Augusta

Chicago

Winfield

Wichita

New Orleans

Boston

Ann Arbor

Grand Rapids

Jackson

St Louis

Lebanon

Edison

Brooklyn

Rochester

Chapel Hill

Durham

Winston-Salem

Columbus

Oklahoma City

Portland

Hershey

Philadelphia

Memphis

Nashville

Dallas

San Antonio

Temple

Madison

Melbourne

Linz

Brussels

Ghent

Leuven

Brno

Prague

Bonn

Kork

Tübingen

Vilnius

Barcelona

Madrid

Valencia

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT01999777 - Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU | Biotech Hunter | Biotech Hunter